The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms

Carcinogenesis

Volumn 32, Issue 5, 2011, Pages 732-740

  Kovacevic, Zaklina ^a   Sivagurunathan, Sutharshani ^a   Mangs, Helena ^a   Chikhani, Sherin ^a   Zhang, Daohai ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MYC PROTEIN; PROTEASOME; PROTEIN MDM2; PROTEIN P21; PROTEIN P50; PROTEIN P53; PROTEIN P63; SHORT HAIRPIN RNA;

ANTINEOPLASTIC ACTIVITY; ANTITUMOR GENE; ARTICLE; CANCER CELL; CARCINOMA CELL; CELL MIGRATION; CELL TYPE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME DEGRADATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; MYC DOWNSTREAM REGULATED GENE 1; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 79955770381     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr046     Document Type: Article

References (57)

1. Bandyopadhyay,S. et al. (2003) The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res., 63, 1731-1736.
2. Bandyopadhyay,S. et al. (2004) Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene, 23, 5675-5681.
3. Bandyopadhyay,S. et al. (2006) The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer. Cancer Res., 66, 11983-11990.
4. Guan,R.J. et al. (2000) Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res., 60, 749-755.
5. Maruyama,Y. et al. (2006) Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res., 66, 6233-6242.
6. Stein,S. et al. (2004) NDRG1 is necessary for p53-dependent apoptosis. J. Biol. Chem., 279, 48930-48940.
7. Shah,M.A. et al. (2005) Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin. Cancer Res., 11, 3296-3302.
8. Kovacevic,Z. et al. (2006) The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis, 6, 1982-1994.
9. Kovacevic,Z. et al. (2008) The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim. Biophys. Acta, 1783, 1981-1992.
10. Le,N.T. et al. (2004) Iron chelators with high antiproliferative activity upregulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood, 104, 2967-2975.
11. Yuan,J. et al. (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood, 104, 1450-1458.
12. Whitnall,M. et al. (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl Acad. Sci. USA, 103, 14901-14906.
13. El-Deiry,W.S. et al. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
14. el-Deiry,W.S. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
15. Abbas,T. et al. (2009) p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer, 9, 400-414.
16. Fukui,R. et al. (1997) Inhibition of smooth muscle cell migration by the p21 cyclin-dependent kinase inhibitor (Cip1). Atherosclerosis, 132, 53-59.
17. Woods,J.M. et al. (2006) A cell-cycle independent role for p21 in regulating synovial fibroblast migration in rheumatoid arthritis. Arthritis Res. Ther., 8, R113.
18. Engelman,R.W. et al. (2007) Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice. Exp. Mol. Pathol., 82, 234-244.
19. Jin,Y. et al. (2003) MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J., 22, 6365-6377.
20. Ellen,T.P. et al. (2008) NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis, 29, 2-8.
21. Taplick,J. et al. (2001) Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. J. Mol. Biol., 308, 27-38.
22. Gao,J. et al. (2001) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood, 98, 842-850.
23. Fu,D. et al. (2007) Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood, 110, 752-761.
24. Liang,S.X. et al. (2003) The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis, 24, 1601-1614.
25. Richardson,D. et al. (1994) The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res., 54, 685-689.
26. Richardson,D.R. et al. (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 86, 4295-4306.
27. Richardson,D.R. et al. (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood, 89, 3025-3038.
28. Dunn,L.L. et al. (2006) The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. Carcinogenesis, 27, 2157-2169.
29. Bambang,I.F. et al. (2009) Cytokeratin 19 regulates endoplasmic reticulum stress and inhibits ERp29 expression via p38 MAPK/XBP-1 signaling in breast cancer cells. Exp. Cell Res., 315, 1964-1974.
30. Kachhap,S.K. et al. (2007) The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS One, 2, e844.
31. Murray,J.T. et al. (2004) Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem. J., 384, 477-488.
32. Sugiki,T. et al. (2004) N-myc downregulated gene 1 is a phosphorylated protein in mast cells. Biol. Pharm. Bull., 27, 624-627.
33. van Bokhoven,A. et al. (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate, 57, 205-225.
34. Chellappan,S.P. et al. (1998) Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development. Curr. Top. Microbiol. Immunol., 227, 57-103.
35. Sherr,C.J. et al. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev., 13, 1501-1512.
36. Kodiha,M. et al. (2009) Optimized immunofluorescence staining protocol to detect the nucleoporin Nup98 in different subcellular compartments. Nat. Protoc. doi:10.1038/nprot.2009.16.
37. Yang,A. et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell, 2, 305-316.
38. Ying,H. et al. (2005) DNA-binding and transactivation activities are essential for TAp63 protein degradation. Mol. Cell. Biol., 25, 6154-6164.
39. Pochampally,R. et al. (1998) A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene, 17, 2629-2636.
40. Bartel,F. et al. (2002) Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell, 2, 9-15.
41. Zhang,Z. et al. (2004) MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem., 279, 16000-16006.
42. Evans,S.C. et al. (2001) An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene, 20, 4041-4049.
43. Hastak,K. et al. (2005) Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J., 19, 789-791.
44. Berger,J.C. et al. (2005) Metastasis suppressor genes: from gene identification to protein function and regulation. Cancer Biol. Ther., 4, 805-812.
45. Elford,H.L. et al. (1970) Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J. Biol. Chem., 245, 5228-5233.
46. van Kempen,L.C. et al. (2002) MMP9 potentiates pulmonary metastasis formation. Cancer Cell, 2, 251-252.
47. Rosenkilde,M.M. et al. (2004) The chemokine system - a major regulator of angiogenesis in health and disease. APMIS, 112, 481-495.
48. Bosnar,M.H. et al. (2009) Subcellular localization of Nm23/NDPK A and B isoforms: a reflection of their biological function? Mol. Cell. Biochem., 329, 63-71.
49. Qu,X. et al. (2002) Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol. Cell. Biochem., 229, 35-44.
50. Tu,L.C. et al. (2007) Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol. Cell. Proteomics, 6, 575-588.
51. Soussi,T. et al. (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer, 1, 233-240.
52. Lowe,S.W. et al. (1994) p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810.
53. Dangi-Garimella,S. et al. (2009) Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J., 28, 347-358.
54. Jackson,R.J. et al. (2003) p21Cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res., 63, 3021-3025.
55. LaBaer,J. et al. (1997) New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11, 847-862.
56. Zhang,H. et al. (1994) p21-containing cyclin kinases exist in both active and inactive states. Genes Dev., 8, 1750-1758.
57. Zhong,Z. (2010) Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res., 70, 2105-2114.